In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. In seeking to identify an underlying mechanism in psilocybin’s effects, neuroinflammatory markers for migraine headache will be measured.
Topic Headache Disorders
Pain
Compound Placebo
Psilocybin
Country China
Visit trial
Status
Not yet recruiting
Results Published
No
Start date
15 July 2021
End date
15 July 2023
Chance of happening
90%
Phase
Phase I
Design
Blinded
Type
Interventional
Generation
First
Participants
24
Sex
All
Age
21- 65
Therapy
No
Trial Details
Migraine headache is a common medical condition and a top cause of disability worldwide. Treatment options for migraine headache are many and varied, though an approximated 10% of migraineurs is refractory to medication and thus, there is a need to develop alternative treatments. There is anecdotal evidence supporting lasting therapeutic effects after limited dosing of psilocybin and related compounds in headache disorders. The cause of this unique effect remains unknown, though the drug class has demonstrable anti-inflammatory activity, a biological process relevant to migraine and other headache disorders. In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. In seeking to identify an underlying mechanism in psilocybin's effects, neuroinflammatory markers for migraine headache will be measured. The results from this study will serve in the development of larger investigations seeking to understand the effects of psilocybin and related compounds in headache disorders.NCT Number NCT04218539
Measures Used
5-Dimensional Altered States of Consciousness QuestionnaireThe 5D-ASC scale measures altered states of consciousness and contains 94 items (visual analog scales).